EDAP TMS traded at $4.40 this Tuesday February 3rd, decreasing $0.08 or 1.79 percent since the previous trading session. Looking back, over the last four weeks, EDAP TMS lost 23.94 percent. Over the last 12 months, its price rose by 80.33 percent. Looking ahead, we forecast EDAP TMS to be priced at 4.09 by the end of this quarter and at 3.78 in one year, according to Trading Economics global macro models projections and analysts expectations.
EDAP TMS S.A. (EDAP) is a company that develops, manufactures, promotes and distributes minimally-invasive medical devices for urology based upon proprietary ultrasound technology. The Company operates worldwide via an extensive network of corporate offices, subsidiaries and distribution partners. The Company invests in Research & Development, partnering with INSERM French public laboratory and international medical research institutions. Company's activity is organized in two divisions: HIFU and UDS (including lithotripsy activities). The Company is developing HIFU technology (High Intensity Focused Ultrasound) in non-invasive treatment of prostate conditions with its range of Robotic HIFU devices, Ablatherm Fusion and Focal One. The Company is also developing ESWL (Extracorporeal ShockWave Lithotripsy) and Stone Laser that offers a range of minimally invasive solutions covering the full scope of urinary tract stone indications.